Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

Shares of Incyte Corp. slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the stock ...

What Happened? Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports.They currently have a hold rating on the ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...